Tags : Lannett

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More

PharmaShots Weekly Snapshot (Jun 08- 12, 2020)

 1. Medtronic Receives CE Mark for MiniMed 780G Insulin Pump to Treat Type 1 Diabetes                                                Published: Jun 11, 2020 | Tags: Medtronic, Receives, CE, Mark, MiniMed 780G, Insulin Pump, Treat, Type 1 Diabetes 2.  Takeda to Divest OTC and Select Non-core Assets to Celltrion for ~ $278M        Published: Jun 11, 2020 | Tags: Takeda, Divest, [&Read More

Insights+ Key Biosimilars Events of December 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More

Lannett Reports Results of Biosimilar Insulin Glargine in Human Clinical

Shots: The first clinical study in humans involves evaluation of PK/PD of the Lannett/HEC-insulin glargine vs the reference product, Sanofi’s US approved Lantus after a single SC dose in 27 healthy male adult candidates The study resulted in meeting all 1EPs i.e, demonstrating bio-similarity to Sanofi’s Lantus and is safe and well-tolerated with no SAEs […]Read More